We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Veradigm (MDRX) & MedAllies Partner for Better Care Decisions
Read MoreHide Full Article
Veradigm (MDRX - Free Report) selected MedAllies, a leading healthcare interoperability and connectivity services provider, as its Qualified Health Information Network (QHIN) partner.
The initiative will improve point-of-care decision-making by clinicians, utilizing Veradigm's electronic health records (EHR) platform and access to a greater range of patient data, such as medication lists and medical histories. This will close more care gaps and improve interoperability across the healthcare sector.
Price Performance
For the past six months, Veradigm’s shares have plunged 17% against the industry’s growth of 14.8%.
Image Source: Zacks Investment Research
More on the News
MedAllies was recently designated as a QHIN under the Trusted Exchange Framework and Common Agreement. Healthcare stakeholders can securely and reliably communicate correct patient data through QHINs, which facilitates more informed patient-care decisions. QHINs connect directly to each other to ensure interoperability between the networks they represent.
Veradigm selecting MedAllies as its QHIN partner will likely lead to improved decision-making for the providers using Veradigm’s EHRs as a greater range of patient and medication-related data can be accessed.
MedAllies connectivity services help Veradigm provide reliable, secure, and trustworthy critical patient data to its clients. MedAllies platform’s document retrieval and record location services can help clients access the information quickly and efficiently to make better decisions.
More on MedAllies
To provide patients with high-quality care, MedAllies is essential in guaranteeing the safe transfer of vital health information via national networks that facilitate seamless data sharing and interoperability across healthcare stakeholders.
The company serves more than 800 hospitals, 5,000 organizations, and 125,000 healthcare providers and collaborates with numerous partners to provide a more patient-centered healthcare experience.
Industry Prospects
A report by Grand View Research points out that the global electronic health records market size was estimated at $28.1 billion in 2022, and it is anticipated to witness a compound annual growth rate (CAGR) of 4.1% from 2023 to 2030. Government initiatives to encourage healthcare IT usage are a key driver in this market. Moreover, the introduction of technologically advanced healthcare services is also expected to drive EHR market growth.
Notable Developments
Veradigm recently announced its strategic acquisition of Koha Health, a full-service revenue cycle management company. This move is likely to solidify Veradigm's position in the ambulatory healthcare market and underscore its commitment to delivering comprehensive revenue cycle services.
In November 2023, Veradigm announced a new solution, Veradigm Intelligent Payments, a bundle of financial communications and payment solutions, that is now available within Veradigm Payerpath via a collaboration with RevSpring. The company, through the new solution, aims to help increase payment rates, accelerate time to payment and reduce manual reconciliation time for healthcare providers.
Some better-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Biodesix (BDSX - Free Report) and Integer Holdings Corporation (ITGR - Free Report) .
DaVita, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 17.3%. DVA’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 36.55%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have gained 42.7% in the past year compared with the industry’s 9.6% growth.
Biodesix, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 32.3% for 2024. BDSX’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 9.76%.
Biodesix’s shares have lost 13.2% in the past year compared with the industry’s 3.2% decline.
Integer Holdings, holding a Zacks Rank of 2 at present, has an estimated long-term growth rate of 15.8%. ITGR’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.9%.
Integer Holdings’ shares have rallied 43.5% in the past year against the industry’s 3.7% decline.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Veradigm (MDRX) & MedAllies Partner for Better Care Decisions
Veradigm (MDRX - Free Report) selected MedAllies, a leading healthcare interoperability and connectivity services provider, as its Qualified Health Information Network (QHIN) partner.
The initiative will improve point-of-care decision-making by clinicians, utilizing Veradigm's electronic health records (EHR) platform and access to a greater range of patient data, such as medication lists and medical histories. This will close more care gaps and improve interoperability across the healthcare sector.
Price Performance
For the past six months, Veradigm’s shares have plunged 17% against the industry’s growth of 14.8%.
Image Source: Zacks Investment Research
More on the News
MedAllies was recently designated as a QHIN under the Trusted Exchange Framework and Common Agreement. Healthcare stakeholders can securely and reliably communicate correct patient data through QHINs, which facilitates more informed patient-care decisions. QHINs connect directly to each other to ensure interoperability between the networks they represent.
Veradigm selecting MedAllies as its QHIN partner will likely lead to improved decision-making for the providers using Veradigm’s EHRs as a greater range of patient and medication-related data can be accessed.
MedAllies connectivity services help Veradigm provide reliable, secure, and trustworthy critical patient data to its clients. MedAllies platform’s document retrieval and record location services can help clients access the information quickly and efficiently to make better decisions.
More on MedAllies
To provide patients with high-quality care, MedAllies is essential in guaranteeing the safe transfer of vital health information via national networks that facilitate seamless data sharing and interoperability across healthcare stakeholders.
The company serves more than 800 hospitals, 5,000 organizations, and 125,000 healthcare providers and collaborates with numerous partners to provide a more patient-centered healthcare experience.
Industry Prospects
A report by Grand View Research points out that the global electronic health records market size was estimated at $28.1 billion in 2022, and it is anticipated to witness a compound annual growth rate (CAGR) of 4.1% from 2023 to 2030. Government initiatives to encourage healthcare IT usage are a key driver in this market. Moreover, the introduction of technologically advanced healthcare services is also expected to drive EHR market growth.
Notable Developments
Veradigm recently announced its strategic acquisition of Koha Health, a full-service revenue cycle management company. This move is likely to solidify Veradigm's position in the ambulatory healthcare market and underscore its commitment to delivering comprehensive revenue cycle services.
In November 2023, Veradigm announced a new solution, Veradigm Intelligent Payments, a bundle of financial communications and payment solutions, that is now available within Veradigm Payerpath via a collaboration with RevSpring. The company, through the new solution, aims to help increase payment rates, accelerate time to payment and reduce manual reconciliation time for healthcare providers.
Veradigm Inc. Price
Veradigm Inc. price | Veradigm Inc. Quote
Zacks Rank & Stocks to Consider
MDRX presently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Biodesix (BDSX - Free Report) and Integer Holdings Corporation (ITGR - Free Report) .
DaVita, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 17.3%. DVA’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 36.55%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have gained 42.7% in the past year compared with the industry’s 9.6% growth.
Biodesix, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 32.3% for 2024. BDSX’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 9.76%.
Biodesix’s shares have lost 13.2% in the past year compared with the industry’s 3.2% decline.
Integer Holdings, holding a Zacks Rank of 2 at present, has an estimated long-term growth rate of 15.8%. ITGR’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.9%.
Integer Holdings’ shares have rallied 43.5% in the past year against the industry’s 3.7% decline.